Chapter 5 84 Figure 1. Overall survival (a), local recurrence free survival (b) and metastasis-free survival (c) in LRRC patients without metastases, with a history of metastases and with synchronous metastases. | 1125 emo)reirradiation for the LRRC than patients tastases, who underwent full-course (chemo) ften (P = 0.012). Intraoperative radiotherapy % of the patients. A multivisceral resection was tients; details about the organs resected with Location and treatment of metastases Details about the types of metastases are shown in Table 3. The majority of the patients with a history of metastases had liver metastases (n = 23, 54%), which were mainly treated with metastasectomy survival (a), survival (b) and val (c) in LRRC astases, with es and with ses Overall survival (A) (B) 1,0 0,8 0,6 0,4 0,2 0,0 1,0 0,8 0,6 0,4 0,2 0,0 1,0 0,8 0,6 0,4 0,2 0,0 0 261 42 46 39 40 237 Local recurrence free survival (C) Metastasis free survival 6 12 211 37 31 25 34 187 18 24 155 28 21 13 22 133 117 19 11 30 36 months 0 261 41 34 31 214 164 19 21 11 13 126 106 11 7 4 3 8 6 88 71 46 6 12 18 24 30 36 months 0 261 41 46 27 34 215 163 22 9 5 14 122 101 10 3 2 7 82 73 6 2 6 12 18 24 30 36 months P<0.001 P=0.129 P=0.253 no metastases history of metastases synchronous metastases no metastases history of metastases synchronous metastases no metastases history of metastases synchronous metastases No. at risk No metastases History of metastases Synchronous metastases No. at risk No metastases History of metastases Synchronous metastases No. at risk No metastases History of metastases Synchronous metastases
RkJQdWJsaXNoZXIy MTk4NDMw